PRECISIONheor, Los Angeles, CA, United States.
PRECISIONheor, New York, NY, United States.
J Med Internet Res. 2021 Feb 3;23(2):e18119. doi: 10.2196/18119.
Evaluation of patients with serious mental illness (SMI) relies largely on patient or caregiver self-reported symptoms. New digital technologies are being developed to better quantify the longitudinal symptomology of patients with SMI and facilitate disease management. However, as these new technologies become more widely available, psychiatrists may be uncertain about how to integrate them into daily practice. To better understand how digital tools might be integrated into the treatment of patients with SMI, this study examines a case study of a successful technology adoption by physicians: endocrinologists' adoption of digital glucometers.
This study aims to understand the key facilitators of and barriers to clinician and patient adoption of digital glucose monitoring technologies to identify lessons that may be applicable across other chronic diseases, including SMIs.
We conducted focus groups with practicing endocrinologists from 2 large metropolitan areas using a semistructured discussion guide designed to elicit perspectives of and experiences with technology adoption. The thematic analysis identified barriers to and facilitators of integrating digital glucometers into clinical practice. Participants also provided recommendations for integrating digital health technologies into clinical practice more broadly.
A total of 10 endocrinologists were enrolled: 60% (6/10) male; a mean of 18.4 years in practice (SD 5.6); and 80% (8/10) working in a group practice setting. Participants stated that digital glucometers represented a significant change in the treatment paradigm for diabetes care and facilitated more effective care delivery and patient engagement. Barriers to the adoption of digital glucometers included lack of coverage, provider reimbursement, and data management support, as well as patient heterogeneity. Participant recommendations to increase the use of digital health technologies included expanding reimbursement for clinician time, streamlining data management processes, and customizing the technologies to patient needs.
Digital glucose monitoring technologies have facilitated more effective, individualized care delivery and have improved patient engagement and health outcomes. However, key challenges faced by the endocrinologists included lack of reimbursement for clinician time and nonstandardized data management across devices. Key recommendations that may be relevant for other diseases include improved data analytics to quickly and accurately synthesize data for patient care management, streamlined software, and standardized metrics.
严重精神疾病(SMI)患者的评估在很大程度上依赖于患者或照护者的自我报告症状。新的数字技术正在被开发出来,以更好地量化 SMI 患者的纵向症状,并促进疾病管理。然而,随着这些新技术的广泛应用,精神科医生可能不确定如何将其整合到日常实践中。为了更好地了解数字工具如何融入 SMI 患者的治疗,本研究通过内分泌医生成功采用数字血糖仪的案例研究来考察这一问题。
本研究旨在了解临床医生和患者采用数字血糖监测技术的关键促进因素和障碍,以确定可能适用于其他慢性疾病(包括 SMI)的经验教训。
我们使用半结构化讨论指南对来自两个大都市地区的执业内分泌医生进行了焦点小组讨论,旨在引出他们对技术采用的看法和经验。主题分析确定了将数字血糖仪整合到临床实践中的障碍和促进因素。参与者还就更广泛地将数字健康技术整合到临床实践中提出了建议。
共纳入 10 名内分泌医生:男性占 60%(6/10);平均从业时间为 18.4 年(标准差 5.6);80%(8/10)在团体实践环境中工作。参与者表示,数字血糖仪代表了糖尿病治疗范式的重大改变,并促进了更有效的护理交付和患者参与。采用数字血糖仪的障碍包括缺乏覆盖范围、提供者报销和数据管理支持,以及患者的异质性。参与者增加数字健康技术使用的建议包括扩大对临床医生时间的报销、简化数据管理流程以及根据患者需求定制技术。
数字血糖监测技术促进了更有效、个性化的护理交付,并改善了患者的参与度和健康结果。然而,内分泌医生面临的主要挑战包括缺乏对临床医生时间的报销和设备之间非标准化的数据管理。可能适用于其他疾病的关键建议包括改进数据分析,以快速准确地为患者护理管理综合数据、简化软件和标准化指标。